Skip to main content

Advertisement

SpringerLink
Log in

Antimetastatic effect of suicide gene therapy for mouse mammary cancers requires T-cell-mediated immune responses

  • Original Paper
  • Published:
Medical Molecular Morphology Aims and scope Submit manuscript

Abstract

These experiments were conducted to investigate whether the antimetastatic effects of HSVtk/GCV therapy involve T-cell-mediated immune responses. In the first experiment, immunocompetent syngeneic mice were inoculated with metastatic mammary cancers, then given a direct intratumoral injection of a plasmid vector containing a suicide gene (pHSVtk) or control vector once a week for 8 weeks. Gene electrotransfer treatment was applied to the tumors, and mice were administered ganciclovir (GCV) using a mini-osmotic pump. At the end of the experiment, tumor volume was significantly lower in the pHSVtk/GCV group. Macrophage accumulations were frequently observed in the peripheries of the necrotic regions in pHSVtk-transfected mice. Levels of CD4 and CD8 proteins in tumors were higher in the pHSVtk/GCV group than in the control group. Interleukin (IL)-12 mRNA levels tended to be higher in tumors in the pHSVtk/GCV group, but there were large variations. Tumor microvessel density was significantly lower in the pHSVtk/GCV group. The numbers of dilated lymphatic vessels containing intraluminal tumor cells tended to be higher in the pHSVtk/GCV group. However, vascular endothelial growth factor (VEGF)-A and VEGF-C mRNA levels in tumors were similar in the control and pHSVtk/GCV groups. In the second experiment, tumor volume and metastatic parameters were compared for immunocompetent syngeneic mice and immunodeficient athymic mice (without an intact T-cell system) given pHSVtk/GCV therapy. Although tumor volumes were significantly smaller in both syngeneic and athymic mice given pHSVtk/GCV therapy, the inhibition ratios (relative to control mice) were much greater in syngeneic mice than in athymic mice. No suppression of metastasis to the lymph nodes and lungs was observed for athymic mice given pHSVtk/GCV therapy. Our data suggest that HSVtk/GCV suicide gene therapy exerts an antimetastatic effect via a T-cell-mediated immune response.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Moolten I (1994) Drug sensitivity (“suicide”) genes for selective cancer therapy. Cancer Gene Ther 1:107–112

    Google Scholar 

  2. Culver KW, Ram Z, Wallbridge S, Ishii H, Oldfield EH, Blaese RM (1992) In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science 256:1550–1552

    Article  PubMed  CAS  Google Scholar 

  3. Freeman SM, Ramesh R, Marrogi AJ (1997) Immune system in suicide-gene therapy. Lancet 349:2–3

    Article  PubMed  CAS  Google Scholar 

  4. Yamamoto S, Suzuki S, Hoshino A, Akimoto M, Shimada T (1997) Herpes simplex virus thymidine kinase/ganciclovir-mediated killing of tumor cell induces tumor-specific cytotoxic T cells in mice. Cancer Gene Ther 4:91–96

    PubMed  Google Scholar 

  5. Mesnil M, Piccoli C, Tiraby G, Willecke K, Yamasaki H (1996) Bystander killing of cancer cells by herpes simplex virus thymidine kinase gene is mediated by connexins. Proc Natl Acad Sci U S A 93:1831–1835

    Article  PubMed  CAS  Google Scholar 

  6. Freeman SM, Abboud CN, Whartenby KA, Packman CH, Koeplin DS, Moolten FL, Abraham GN (1993) The “bystander effect”: tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res 53:5274–5283

    PubMed  CAS  Google Scholar 

  7. Shibata MA, Morimoto J, Otsuki Y (2002) Suppression of murine mammary carcinoma growth and metastasis by HSVtk/GCV gene therapy using in vivo electroporation. Cancer Gene Ther 9:16–27

    Article  PubMed  CAS  Google Scholar 

  8. Shibata MA, Morimoto J, Doi H, Morishima S, Naka M, Otsuki Y (2007) Electrogene therapy using endostatin, with or without suicide gene therapy, suppresses murine mammary tumor growth and metastasis. Cancer Gene Ther 14:268–278

    Article  PubMed  CAS  Google Scholar 

  9. Colombo F, Barzon L, Franchin E, Pacenti M, Pinna V, Danieli D, Zanusso M, Palu G (2005) Combined HSV-TK/IL-2 gene therapy in patients with recurrent glioblastoma multiforme: biological and clinical results. Cancer Gene Ther 12:835–848

    Article  PubMed  CAS  Google Scholar 

  10. Shibata MA, Ito Y, Morimoto J, Otsuki Y (2004) Lovastatin inhibits tumor growth and lung metastasis in mouse mammary carcinoma model: a p53-independent mitochondrial-mediated apoptotic mechanism. Carcinogenesis (Oxf) 25:1887–1898

    Article  CAS  Google Scholar 

  11. Morimoto J, Imai S, Haga S, Iwai Y, Iwai M, Hiroishi S, Miyashita N, Moriwaki K, Hosick HL (1991) New murine mammary tumor cell lines. In Vitro Cell Dev Biol 27A:349–351

    Article  PubMed  CAS  Google Scholar 

  12. Shibata MA, Akao Y, Shibata E, Nozawa Y, Ito T, Mishima S, Morimoto J, Otsuki Y (2007) Vaticanol C, a novel resveratrol tetramer, reduces lymph node and lung metastases of mouse mammary carcinoma carrying p53 mutation. Cancer Chemother Pharmacol 60:681–691

    Article  PubMed  CAS  Google Scholar 

  13. Shibata MA, Morimoto J, Ito Y, Kusakabe K, Otsuki Y (2004) Experimental gene therapy in mammary and urinary bladder cancer using electrogene transfer. Med Electron Microsc 37: 216–224

    Article  PubMed  CAS  Google Scholar 

  14. Shibata MA, Ito Y, Morimoto J, Kusakabe K, Yoshinaka R, Otsuki Y (2006) In vivo electrogene transfer of interleukin-12 inhibits tumor growth and lymph node and lung metastases in mouse mammary carcinomas. J Gene Med 8:335–352

    Article  PubMed  CAS  Google Scholar 

  15. Shibata MA, Liu M-L, Knudson MC, Shibata E, Yoshidome K, Bandy T, Korsmeyer SJ, Green JE (1999) Haploid loss of bax leads to accelerated mammary tumor development in C3(1)/SV40-Tag transgenic mice: reduction in protective apoptotic response at the preneoplastic stage. EMBO J 18:2692–2701

    Article  PubMed  CAS  Google Scholar 

  16. Gorrin-Rivas MJ, Arii S, Furutani M, Mizumoto M, Mori A, Hanaki K, Maeda M, Furuyama H, Kondo Y, Imamura M (2000) Mouse macrophage metalloelastase gene transfer into a murine melanoma suppresses primary tumor growth by halting angiogenesis. Clin Cancer Res 6:1647–1654

    PubMed  CAS  Google Scholar 

  17. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25:402–408

    Article  PubMed  CAS  Google Scholar 

  18. Shibata MA, Horiguchi T, Morimoto J, Otsuki Y (2003) Massive apoptotic cell death in chemically induced rat urinary bladder carcinomas following in situ HSVtk electrogene transfer. J Gene Med 5:219–231

    Article  PubMed  CAS  Google Scholar 

  19. Kuriyama S, Kikukawa M, Masui K, Okuda H, Nakatani T, Akahane T, Mitoro A, Tominaga K, Tsujinoue H, Yoshiji H, Okamoto S, Fukui H, Ikenaka K (1999) Cancer gene therapy with HSV-tk/GCV system depends on T-cell-mediated immune responses and causes apoptotic death of tumor cells in vivo. Int J Cancer 83:374–380

    Article  PubMed  CAS  Google Scholar 

  20. Fogar P, Greco E, Basso D, Habeler W, Navaglia F, Zambon CF, Tormen D, Gallo N, Cecchetto A, Plebani M, Pedrazzoli S (2003) Suicide gene therapy with HSV-TK in pancreatic cancer has no effect in vivo in a mouse model. Eur J Surg Oncol 29:721–730

    Article  PubMed  CAS  Google Scholar 

  21. Colombo MP, Trinchieri G (2002) Interleukin-12 in anti-tumor immunity and immunotherapy. Cytokine Growth Factor Rev 13: 155–168

    Article  PubMed  CAS  Google Scholar 

  22. Nastala CL, Edington HD, McKinney TG, Tahara H, Nalesnik MA, Brunda MJ, Gately MK, Wolf SF, Schreiber RD, Storkus WJ (1994) Recombinant IL-12 administration induces tumor regression in association with IFN-γ production. J Immunol 153: 1697–1706

    PubMed  CAS  Google Scholar 

  23. Ikeda H, Old LJ, Schreiber RD (2002) The roles of IFN gamma in protection against tumor development and cancer immunoediting. Cytokine Growth Factor Rev 13:95–109

    Article  PubMed  CAS  Google Scholar 

  24. Rook G, Balkwill F (1998) Cell-mediated immune reactions, 5th edn. Mosby, London

    Google Scholar 

  25. Coughlin CM, Wysocka M, Trinchieri G, Lee WM (1997) The effect of interleukin 12 desensitization on the antitumor efficacy of recombinant interleukin 12. Cancer Res 57:2460–2467

    PubMed  CAS  Google Scholar 

  26. Boggio K, Nicoletti G, Di Carlo E, Cavallo F, Landuzzi L, Melani C, Giovarelli M, Rossi I, Nanni P, De Giovanni C, Bouchard P, Wolf S, Modesti A, Musiani P, Lollini PL, Colombo MP, Forni G (1998) Interleukin 12-mediated prevention of spontaneous mammary adenocarcinomas in two lines of Her-2/neu transgenic mice. J Exp Med 188:589–596

    Article  PubMed  CAS  Google Scholar 

  27. Roy EJ, Gawlick U, Orr BA, Rund LA, Webb AG, Kranz DM (2000) IL-12 treatment of endogenously arising murine brain tumors. J Immunol 165:7293–7299

    PubMed  CAS  Google Scholar 

  28. Salven P, Lymboussaki A, Heikkila P, Jaaskela-Saari H, Enholm B, Aase K, von Euler G, Eriksson U, Alitalo K, Joensuu H (1998) Vascular endothelial growth factors VEGF-B and VEGF-C are expressed in human tumors. Am J Pathol 153:103–108

    PubMed  CAS  Google Scholar 

  29. Valtola R, Salven P, Heikkila P, Taipale J, Joensuu H, Rehn M, Pihlajaniemi T, Weich H, deWaal R, Alitalo K (1999) VEGFR-3 and its ligand VEGF-C are associated with angiogenesis in breast cancer. Am J Pathol 154:1381–1390

    PubMed  CAS  Google Scholar 

  30. Kaipainen A, Korhonen J, Mustonen T, van Hinsbergh VW, Fang GH, Dumont D, Breitman M, Alitalo K (1995) Expression of the fms-like tyrosine kinase 4 gene becomes restricted to lymphatic endothelium during development. Proc Natl Acad Sci U S A 92: 3566–3570

    Article  PubMed  CAS  Google Scholar 

  31. Voest EE, Kenyon BM, O’Reilly MS, Truitt G, D’Amato RJ, Folkman J (1995) Inhibition of angiogenesis in vivo by interleukin 12. J Natl Cancer Inst 87:581–586

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Anatomy and Cell Biology, Division of Basic Medicine I, Osaka Medical College, 2-7 Daigaku-machi, Takatsuki, Osaka, 569-8686, Japan

    Masa-Aki Shibata, Kanako Akamatsu & Yoshinori Otsuki

  2. High-Tech Research Center, Osaka Medical College, Osaka, Japan

    Yoshinori Otsuki

  3. Laboratory Animal Center, Osaka Medical College, Osaka, Japan

    Junji Morimoto

Authors
  1. Masa-Aki Shibata
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Junji Morimoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kanako Akamatsu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yoshinori Otsuki
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yoshinori Otsuki.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Shibata, MA., Morimoto, J., Akamatsu, K. et al. Antimetastatic effect of suicide gene therapy for mouse mammary cancers requires T-cell-mediated immune responses. Med Mol Morphol 41, 34–43 (2008). https://doi.org/10.1007/s00795-007-0388-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00795-007-0388-1

Key words

Search

Navigation